<DOC>
	<DOCNO>NCT02601885</DOCNO>
	<brief_summary>This study seek evaluate safety , tolerability , pharmacokinetics ( PK ) immunogenicity ABT-555 participant relapse form multiple sclerosis ( RFMS ) .</brief_summary>
	<brief_title>A Multiple Dose Study ABT-555 Subjects With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Currently receive one follow MS medication least 3 month : betainterferon ( formulation include pegylated form ) , glatiramer acetate ( Copaxone® , others ) , teriflunomide ( Aubagio® ) , fingolimod ( Gilenya® ) , dimethyl fumarate ( Tecfidera® ) ; OR Has treat MS immunotherapy past 6 month ( 12 month previously receive cyclophosphamide alemtuzumab ) ; OR Treatment naïve establish MS diagnosis per criterion neurologist . Diagnosis relapsingremitting MS ( RRMS ) secondary progressive MS ( SPMS ) accord revise McDonald criterion Baseline Expanded Disability Status Scale ( EDSS ) 0 6.0 , inclusive . Brain MRI scan Screening show evidence overt vascular lesion , mass , mass effect abnormalities compatible MS , would preclude participant undergoing lumbar puncture/spinal tap CSF collection Diagnosis primary progressive MS . Anticipated maintenance immunomodulator change , either agent dose An MS relapse occur within 30 day prior randomization AND/OR participant stabilize previous relapse prior randomization Participants MRI contraindicate Participants claustrophobia medically manage unable lie still 1 hour imaging procedure Findings brain MRI scan indicate clinically significant brain abnormality MS Contraindication lumbar puncture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Secondary progressive</keyword>
	<keyword>Relapsing-remitting</keyword>
	<keyword>Relapsing form</keyword>
</DOC>